Home › Compare › GBLX vs O

GBLX vs O: Dividend Comparison 2026

GBLX yields 666666.67% · O yields 5.28%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GBLX wins by $3843184858461165056.00M in total portfolio value
10 years
GBLX
GBLX
● Live price
666666.67%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$3843184858461165056.00M
Annual income
$2,951,404,776,098,759,000,000,000.00
Full GBLX calculator →
O
Realty Income Corporation
● Live price
5.28%
Share price
$61.15
Annual div
$3.23
5Y div CAGR
15.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$34.2K
Annual income
$5,102.74
Full O calculator →

Portfolio growth — GBLX vs O

📍 GBLX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodGBLXO
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, GBLX + O cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
GBLX pays
O pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

GBLX
Annual income on $10K today (after 15% tax)
$56,666,666.67/yr
After 10yr DRIP, annual income (after tax)
$2,508,694,059,683,945,000,000,000.00/yr
O
Annual income on $10K today (after 15% tax)
$449.12/yr
After 10yr DRIP, annual income (after tax)
$4,337.33/yr
At 15% tax rate, GBLX beats the other by $2,508,694,059,683,945,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of GBLX + O for your $10,000?

GBLX: 50%O: 50%
100% O50/50100% GBLX
Portfolio after 10yr
$1921592429230582528.00M
Annual income
$1,475,702,388,049,379,400,000,000.00/yr
Blended yield
76.80%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on O right now

GBLX
No analyst data
Altman Z
-1735.9
Piotroski
3/9
O
Analyst Ratings
13
Buy
18
Hold
3
Sell
Consensus: Hold
Price Target
$64.00
+4.7% upside vs current
Range: $60.00 — $69.00
Altman Z
1.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

GBLX buys
0
O buys
0
No recent congressional trades found for GBLX or O in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricGBLXO
Forward yield666666.67% ✓5.28%
Annual dividend / share$2.00$3.23 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%15.1% ✓
Portfolio after 10y$3843184858461165056.00M ✓$34.2K
Annual income after 10y$2,951,404,776,098,759,000,000,000.00 ✓$5,102.74
Total dividends collected$3777696863071325696.00M ✓$20.7K
Payment frequencyquarterlymonthly
SectorStockREIT

Year-by-year: GBLX vs O ($10,000, DRIP)

YearGBLX PortfolioGBLX Income/yrO PortfolioO Income/yrGap
1← crossover$33,344,033$33,333,333.33$10,818$608.16+$33.33M → GBLX
2$51,973,424,741$51,937,746,625.13$11,787$741.68+$51973.41M → GBLX
3$37,885,279,905,810$37,829,668,341,337.28$12,946$911.00+$37885279.89M → GBLX
4$12,926,234,563,052,674$12,885,697,313,553,460.00$14,345$1,127.94+$12926234563.04M → GBLX
5$2,068,281,583,056,657,700$2,054,450,512,074,191,400.00$16,056$1,409.05+$2068281583056.64M → GBLX
6$155,823,080,460,537,230,000$153,610,019,166,666,620,000.00$18,171$1,777.83+$155823080460537.19M → GBLX
7$5,574,621,214,635,156,000,000$5,407,890,518,542,381,000,000.00$20,820$2,268.21+$5574621214635156.00M → GBLX
8$96,370,936,431,909,830,000,000$90,406,091,732,250,210,000,000.00$24,188$2,929.90+$96370936431909824.00M → GBLX
9$833,439,329,310,660,000,000,000$730,322,427,328,516,400,000,000.00$28,533$3,837.11+$833439329310659968.00M → GBLX
10$3,843,184,858,461,165,000,000,000$2,951,404,776,098,759,000,000,000.00$34,235$5,102.74+$3843184858461165056.00M → GBLX

GBLX vs O: Complete Analysis 2026

GBLX — Stock

GB Sciences, Inc. engages in the research and development of plant-based medicines in North America and Europe. The company offers cannabinoid-inspired medicines and complex therapeutic mixtures for the prescription drug market. Its intellectual property covers a range of conditions and programs in pre-clinical animal stage for Parkinson's disease, neuropathic pain, chronic pain, COVID-related cytokine release syndrome, depression/anxiety, and cardiovascular therapeutic programs. The company was formerly known as Growblox Sciences, Inc. and changed its name to GB Sciences, Inc. in October 2016. GB Sciences, Inc. was incorporated in 2001 and is based in Las Vegas, Nevada.

Full GBLX Calculator →

O — REIT

Realty Income, The Monthly Dividend Company, is an S&P 500 company dedicated to providing stockholders with dependable monthly income. The company is structured as a REIT, and its monthly dividends are supported by the cash flow from over 6,500 real estate properties owned under long-term lease agreements with our commercial clients. To date, the company has declared 608 consecutive common stock monthly dividends throughout its 52-year operating history and increased the dividend 109 times since Realty Income's public listing in 1994 (NYSE: O). The company is a member of the S&P 500 Dividend Aristocrats index. Additional information about the company can be obtained from the corporate website at www.realtyincome.com.

Full O Calculator →
📬

Get this GBLX vs O comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

GBLX vs SCHDGBLX vs JEPIGBLX vs KOGBLX vs MAINGBLX vs STAGGBLX vs ADCGBLX vs NNNGBLX vs VICI

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.